Biogen Inc (BIIB – Q3FY20) – TECFIDERA sales decline is expected, impact the revenue growth.

in , on November 20, 2020

TECFIDERA situation in the U.S. is clearly a near-term challenge for the company. During Q3FY20, the company began to experience the impact of generic entrants with more than 10 TECFIDERA generics approved and at least six now in the market, and discounted prices of ~90%.

Executive Summary

Financial Statements

– Income Statement and Forecast
– Balance Sheet
– Cash Flow
– Q3FY20 Results – Overview
– Q3FY20 – Product Revenues
– Q3FY20 – Other Revenues
– Q3FY20 – Key Developments
– FY20 – Guidance
– Conclusion
– GAAP to Non-GAPP Reconciliation

Historical Performance

– Key Ratios
– Profitability Ratios, Asset Turnover Ratio, Growth Ratio
– Per Share Items and Key Ratios
– Key Cash Flow Items
– P/E Band

Product Performance and Key Developments

– Ownership
– Competition
– Key Developments

 Valuation and Consensus Performance

– Analyst Recommendations

Market Price Performance

CrispIdea Coverage

No of Pages : 64

Release Information

  • Released
    :

    November 20, 2020

  • Last Updated
    :

    November 20, 2020